一、审议通过《公司 2024 年度监事会工作报告》 山东东方海洋科技股份有限公司 第八届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届监事会第十一次会 议于 2025 年 4 月 21 日以电话、邮件等形式通知全体监事，会议定于 2025 年 4 月 25 日上午以通讯方式召开，会议应到监事 5 人，实际参加及审议监事 5 人，会议 由监事会主席王顺奎先生召集并主持。本次会议的召集、召开符合《公司法》和 《公司章程》的有关规定。会议以通讯表决方式审议并通过如下决议： 证券代码：002086 证券简称：东方海洋 公告编号：2025-023 监事会认为：2024 年监事会严格按照《公司章程》及《监事会议事规则》的 规定召开监事会，公司监事能够认真履行职责，通过列席董事会、股东大会和对 下属企业的检查，对公司经营、财务运作以及董事会和经营班子履行职责的合法 合规性进行监督。报告期内，未发现公司存在违法违规行为。 表决结果：5 票同意，0 票反对，0 票弃权。 该工作报告需提交公司年度 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-022 山东东方海洋科技股份有限公司 第八届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）第八届董事会第二十次会 议于 2025 年 4 月 21 日以电话、邮件等形式通知全体董事，会议定于 2025 年 4 月 25 日以通讯方式召开，应参加董事 9 人，实际参加审议表决董事 9 人。会议的召集、 召开符合《公司法》和《公司章程》规定，会议由董事长张乐先生召集并主持。会 议以通讯表决方式通过以下议案： 一、审议通过《公司 2024 年度董事会工作报告》 董事会工作报告全面、真实、完整地反映了公司本年度董事会工作情况。具体 内容详见公司《2024 年年度报告》第三节管理层讨论与分析相关章节。 鉴于公司 2024 年度可供股东分配的利润为负，结合公司实际经营发展情况， 公司 2025 年度日常经营对资金的需求较大，为保障公司正常生产经营和稳定发展 需要，更好地维护全体股东的长远利益，建议 2024 年度不派发现金红利，不送 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-016 山东东方海洋科技股份有限公司 关于公司 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东东方海洋科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召 开了第八届董事会第二十次会议、第八届监事会第十一次会议，审议通过了《公 司 2024 年度利润分配预案》。公司董事会、监事会均认为本次利润分配预案符 合《公司法》等法律法规及《公司章程》关于利润分配的相关规定，综合考虑了 公司实际经营情况、未来业务发展及资金需求。本议案尚需提交公司 2024 年度 股东大会审议，现将具体情况公告如下： 为保障公司正常生产经营和未来发展，公司拟定 2024 年度利润分配方案为： 公司 2024 年度拟不派发现金红利，不送红股且不进行资本公积金转增股本。 二、最近三个会计年度现金分红情况 | 项目 | 年度 2024 | 年度 2023 | 年度 2022 | | --- | --- | --- | --- | | 现金分红总额（元） | 0 | ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥75,273,204.39, representing a 12.95% increase compared to ¥66,643,850.46 in the same period last year[5] - The net profit attributable to shareholders was -¥22,099,956.99, a decline of 53.58% from -¥14,389,779.83 year-over-year[5] - The operating profit was -¥22,659,510.40, worsening from -¥14,465,916.86 in the previous period, representing an increase in losses of approximately 56.5%[16] - The net profit attributable to the parent company was -¥22,099,956.99, compared to -¥14,389,779.83 in the previous period, reflecting a decline of approximately 53.5%[16] - The total comprehensive income attributable to the parent company was -¥22,111,834.94, compared to -¥14,304,961.49 in the previous period, indicating a decrease of about 54.1%[17] Cash Flow and Liquidity - The net cash flow from operating activities was -¥54,695,225.37, which is a 19.16% decrease compared to -¥45,898,806.38 in the previous year[5] - Cash flow from operating activities showed a net outflow of -¥54,695,225.37, compared to -¥45,898,806.38 in the previous period, indicating a deterioration in cash flow by about 18.9%[18] - The company received cash from operating activities totaling ¥95,209,947.20, an increase from ¥73,953,579.28 in the previous period, reflecting a growth of about 28.5%[17] - Cash and cash equivalents decreased to ¥312,254,508.42 from ¥404,608,292.25, a decline of about 22.8%[12] - Cash and cash equivalents at the end of the period were ¥87,910,344.68, down from ¥358,430,352.03 at the end of the previous period, a decrease of approximately 75.5%[18] - The net cash flow from financing activities was ¥991,320.00, a significant decrease from ¥269,858,986.67 in the previous period, indicating a decline of approximately 99.6%[18] - The company incurred a total operating cash outflow of ¥149,905,172.57, compared to ¥119,852,385.66 in the previous period, representing an increase of about 25.1%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,735,204,240.75, down 4.76% from ¥1,821,861,787.75 at the end of the previous year[5] - Current liabilities decreased to ¥150,757,002.02 from ¥213,645,371.09, a reduction of approximately 29.4%[13] - Non-current liabilities decreased to ¥163,643,461.87 from ¥166,347,902.63, a decrease of approximately 1.6%[13] - The equity attributable to shareholders decreased by 1.54% to ¥1,409,414,538.22 from ¥1,431,526,373.16 at the end of the previous year[5] Operational Performance - Total operating revenue for the current period reached ¥75,273,204.39, an increase from ¥66,643,850.46 in the previous period, representing a growth of approximately 9.8%[15] - Total operating costs increased to ¥100,826,802.20 from ¥83,618,008.07, reflecting a rise of about 20.5%[15] - The cost of goods sold rose significantly to ¥65,682,585.84 from ¥50,025,307.02, indicating an increase of approximately 31.3%[15] - The company's subsidiary, Avioq, Inc., experienced a significant decline in sales of HTLV test kits, impacting net profit and net profit excluding non-recurring gains and losses[8] Shareholder Information - The total number of common shareholders at the end of the reporting period was 101,588[10] - The basic and diluted earnings per share remained at -¥0.01, unchanged from the previous year[5] - The weighted average return on equity was -1.56%, a decrease of 0.67% compared to -0.89% in the same period last year[5] - The company reported non-recurring gains of ¥2,584,979.85, primarily from government subsidies and other income[7] - The company reported a tax expense of ¥15,531.36, compared to ¥10,203.33 in the previous period, reflecting an increase of approximately 52.8%[16]

Financial Performance - The company's operating revenue for 2024 was ¥340,159,362.15, a decrease of 22.20% compared to ¥437,233,445.62 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥190,379,059.47, representing a decline of 110.88% from ¥1,749,600,271.35 in 2023[22] - The net cash flow from operating activities was -¥193,108,739.30, a significant drop of 318.07% compared to -¥46,190,507.48 in 2023[22] - The total assets at the end of 2024 were ¥1,821,861,787.75, down 32.71% from ¥2,707,578,833.26 at the end of 2023[22] - The net assets attributable to shareholders decreased by 11.49% to ¥1,431,526,373.16 from ¥1,617,399,975.20 in 2023[22] - The basic earnings per share for 2024 was -¥0.10, a decline of 111.24% from ¥0.89 in 2023[22] - The company reported a weighted average return on equity of -12.49% for 2024[22] - The net profit after deducting non-recurring gains and losses was -¥199,611,273.52, an improvement of 68.61% from -¥635,887,563.83 in 2023[22] - The overall financial performance indicates a challenging environment, with significant losses and a need for strategic adjustments to improve profitability[26] Revenue Breakdown - Revenue from the aquaculture segment was ¥74,444,071.28, down 15.50% from ¥88,096,305.46 in the previous year, accounting for 21.89% of total revenue[60] - Revenue from the seafood processing segment increased by 23.73% to ¥159,957,468.48, representing 47.02% of total revenue[60] - Revenue from in vitro diagnostics plummeted by 58.30% to ¥81,217,453.55, making up 23.88% of total revenue[60] - The company achieved a gross margin of 30.87% in the in vitro diagnostics segment, down 28.88% year-over-year[62] - The company’s revenue from domestic trade rose by 50.29% to ¥72,594,721.93, with a gross margin of 12.54%[62] Market and Industry Focus - The company is focusing on the development of marine and health industries, aiming for sustainable growth through technological innovation and industry transformation[36] - The marine aquaculture industry is transitioning towards modern, eco-friendly practices, with a focus on high-quality, standardized production methods[31] - The health industry is experiencing a digital transformation, improving service quality and efficiency through AI and other technologies[35] - The company is committed to expanding its market presence and enhancing its competitive edge in both domestic and international markets[31] - The company is actively expanding its market presence both domestically and internationally, aiming to enhance brand recognition and core competitiveness[41] Research and Development - The company has established 7 national R&D platforms and 11 provincial R&D platforms, strengthening its technological innovation capabilities[50] - The company’s R&D team includes over 70 professionals in the field of biomedicine and in vitro diagnostics, with a focus on innovative technology development[58] - The company is developing a non-invasive test kit for detecting Helicobacter pylori, which is currently in the clinical trial phase[71] - The company is focusing on expanding its product line in vitamin testing, with new assays for both water-soluble and fat-soluble vitamins expected to improve clinical nutritional assessments[73] - The ongoing R&D efforts are expected to strengthen the company's position in the immunodiagnostic field and enhance its brand influence[72] Governance and Management - The company maintains a complete corporate governance structure with independent operation capabilities in finance, procurement, production, and sales[137] - The company has appointed a new financial director effective from June 28, 2024[140] - The company is focused on maintaining independent operations and governance amidst its diverse shareholder base[137] - The company has established specialized committees within its board to enhance governance and decision-making[137] - The company is undergoing a significant management restructuring, with several key positions being filled and replaced as part of the transition[143] Environmental and Social Responsibility - The company adheres to multiple environmental protection laws and standards, ensuring compliance with national and local regulations[177] - The company has implemented advanced environmental management practices to prevent pollution and promote energy conservation[180] - The company actively participates in social responsibility initiatives, contributing to community development and promoting a harmonious corporate culture[183] - The company has conducted regular safety training and inspections to ensure compliance with safety regulations and prevent accidents[183] - The company has established an ISO14001 environmental management system to enhance its environmental management capabilities and competitiveness[181] Challenges and Risks - The company has faced regulatory penalties for non-operational fund occupation and inaccurate performance forecasts[153] - The company acknowledges the challenges posed by environmental factors and resource competition in the marine aquaculture sector[97] - The company faces risks related to disease outbreaks in aquaculture, with potential annual economic losses exceeding 10 billion RMB if not managed properly[118] - The company faces risks in the export processing business due to international economic uncertainties and rising labor costs, impacting market conditions negatively[123] - The company has reported a significant discrepancy between the 2021 performance forecast and the actual audited net profit, leading to a public reprimand[153] Future Outlook - The company is optimistic about the future of the health industry, viewing it as a new growth point for the national economy[105] - The company aims to accelerate the development of in vitro diagnostics and precision medicine, leveraging existing research technology, talent, and quality control systems[106] - The company plans to enhance its market competitiveness by emphasizing standardized, high-precision, and market-oriented processing in its fisheries business[106] - The company aims to provide standardized and cost-effective solutions for thrombotic risk assessment and monitoring of thrombolytic therapy[72] - The company plans to enhance its domestic marketing efforts and expand international sales channels to capture market share[117]

山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 D-二聚体（D-Dimer）测定试剂盒（磁微粒化学发光法）、骨钙素（0C）测定试 剂盒（磁微粒化学发光法）、维生素 B12（VB12）测定试剂盒（磁微粒化学发 光法）、纤维蛋白原降解产物（FDP）测定试剂盒（磁微粒化学发光法）的投产 及对公司业绩的后续影响具有不确定性，请广大投资者注意投资风险。 证券代码：002086 证券简称：东方海洋 公告编号：2025-014 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的 D-二聚体（D-Dimer）测定试剂盒（磁微粒化学 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-013 山东东方海洋科技股份有限公司 诉讼及诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示 1．案件所处的诉讼阶段：①第三人撤销之诉案件：山东省人民检察院已受理；② 第一批投资者诉讼案件：其中新增5名原告已达成诉前调解并经法院确认，另公司对4 名一审原告提出上诉，二审诉讼开庭，尚未作出终审判决/裁定；③第二批投资者诉讼 案件：233名原告法院已结案；33名原告在诉前调解阶段撤诉；57名原告法院已立案， 尚未开庭审理；④普通破产债权确认纠纷案件：法院已立案，尚未开庭审理。 2．上市公司所处的当事人地位：被告；第一批投资者诉讼二审案件为上诉人(一审 被告)。 3．涉案的金额：①第三人撤销之诉案件：撤销支付本金3,000万元、逾期使用费(以 3,000万元为基数，按照年利率24%自2018年9月17日起计算至实际给付之日，并扣除山 东东方海洋集团公司已经完成支付的6万元)、律师费20,000元、保险费135,450元，与其 他被告共同承担案件受理费192,577元。②第一批投资者诉讼 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-012 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 幽门螺杆菌 IgG 抗体检测试剂盒（化学发光法）的投产及对公司业绩的后续影响 具有不确定性，请广大投资者注意投资风险。 1、幽门螺杆菌 IgG 抗体检测试剂盒（化学发光法） 二、对公司的影响 上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域 1 的产品线。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测本次产品对公司未来业绩的具体影响， 请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的幽门螺杆菌 IgG 抗体检测试剂盒（化学发光法）于近日 取得了国家药品监督管理 ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-011 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测本次产品对公司未来业绩的具体影响， 请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的 25-羟基维生素 D（25-OH VD）测定试剂盒（磁微粒化 学发光法）于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册 证（体外诊断试剂），具体情况如下： 一、产品信息 1、25-羟基维生素 D（25-OH VD）测定试剂盒（磁微粒化学发光法） | 产品名称 | 25-羟基维生素 | | D（25-OH VD）测定试剂盒（磁微粒化学发光法） | | | | | | | | --- | --- | --- | --- ...

证券代码：002086 证券简称：东方海洋 公告编号：2025-010 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 幽门螺杆菌（HP）检测试剂盒（脲酶法）的投产及对公司业绩的后续影响具有 不确定性，请广大投资者注意投资风险。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测本次产品对公司未来业绩的具体影响， 请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的幽门螺杆菌（HP）检测试剂盒（脲酶法）于近日取得 了山东省药品监督管理局的注册批准，获得医疗器械注册证（体外诊断试剂）， 具体情况如下： 一、产品信息 产品名称 幽门螺杆菌（HP）检测试剂盒（脲酶法） 注册证编号 鲁械注准 2025240015 ...